PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.91%
Negative revenue growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
0.58%
Gross profit growth of 0.58% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
0.43%
EBIT growth of 0.43% while Medical - Pharmaceuticals median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
-2.15%
Negative operating income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-2.62%
Negative net income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-2.63%
Negative EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-2.63%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.03%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 7.50%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
-4.03%
Negative 5Y CAGR while Medical - Pharmaceuticals median is 8.77%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
-25.88%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 6.65%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 5Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
No Data
No Data available this quarter, please select a different quarter.
90.97%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 42.38% over a decade. Joel Greenblatt might see a standout compounder of earnings.
0.73%
Below 50% of Medical - Pharmaceuticals median. Jim Chanos would suspect deeper problems limiting mid-term profit potential.
-24.36%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 6.51%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
63.24%
Equity/share CAGR of 63.24% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
No Data
No Data available this quarter, please select a different quarter.
-10.18%
Negative 3Y equity/share growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
52.78%
3Y dividend/share CAGR of 52.78% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
5.88%
AR growth of 5.88% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
7.68%
Inventory growth of 7.68% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
-0.22%
Assets shrink while Medical - Pharmaceuticals median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
4.68%
BV/share growth of 4.68% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-9.08%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
1.39%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.